RBC Capital reiterates Chemours stock rating on TiO2 margin outlook By Investing.com

RBC Capital reiterated an Outperform and $21 price target as Chemours shares trade at $21.93 near a 52-week high, up 80.7% YTD. RBC says each $100/ton TiO2 price rise could add >$40M in annual EBITDA (600 kt capacity at ~65% utilization); TZMI forecasts North American TiO2 EBITDA margins >30% in 2026 and European prices rising to $3,630/mt (+9.5% y/y). Chemours completed a $700M 7.875% senior unsecured note offering to redeem $188M of 2028 notes and $500.3M of 2027 notes; Jefferies raised its price target to $17 despite a Q4 EBITDA miss of $13M.

Analysis

The market appears to be re-pricing a cyclical margin recovery into Chemours’ equity while simultaneously underappreciating the single biggest hedge against downside: the company’s fixed‑income carry and covenant profile. If TiO2 pricing and specialty-adoption trends materialize slowly rather than in a single-year inflection, equity upside is limited by leverage but credit returns remain attractive — a classic credit‑rich, equity‑binary situation.

Second‑order winners include distributors and logistics providers that can capture widened spreads if manufacturers elect to outsource variable freight and inventory risk; conversely, integrated lower‑cost chloride producers will exert pricing discipline if end‑market demand falters. Semiconductor‑adjacent specialty chem suppliers are an overlooked upside from the AM→PS shift: material specification changes there are sticky and can sustain premium ASPs for additives and ultra‑high‑purity intermediates beyond the TiO2 cycle.

Key catalysts to watch on 3–18 month horizons are contract renewal windows in North America/Europe (pace of pass‑through), freight rate normalization, and near‑term quarterly EBITDA vs working capital cadence — any meaningful roll‑forward shortfall will reprice equity multiples quickly because leverage magnifies investor reactions. Tail risks include abrupt demand contraction in construction/auto paint or a regulatory/legal headline that reopens legacy environmental liabilities; both would compress multiples and push recovery timelines well past a single fiscal year.

The consensus narrative is that a margin rebound is “baked in”; what’s missing is a pathway that converts EBITDA to free cash flow given working capital dynamics and capex for specialty conversions. That asymmetry argues for strategies that monetize credit carry or buy optionality on upside while capping downside loss on the equity leg.

Key Decisions for Investors

• Pair trade (6–18 months): Long TROX (Tronox) equal‑notional / Short CC equity 0.7x notional — expresses a view that cleaner balance‑sheet TiO2 peers rerate more than a highly levered turnaround story. Target +30% relative performance; stop‑loss if the pair moves 15% against you.
• Credit‑over‑equity (12–36 months): Acquire senior unsecured CC bonds in secondary market and hedge equity beta via index puts or a short equity sleeve. Expected routine carry with pulled‑forward upside if turnaround executes; downside limited to credit deterioration — size exposure to keep recovery rate scenario stress <10% portfolio hit.
• Protected equity (9–12 months): Buy CC shares and construct a collar: sell 1x 9–12 month call ~25% OTM and buy 0.7x put ~20% OTM. Costless or modest premium collar that preserves ~60–80% upside capture while limiting tail loss to defined put strike.
• Event options (3–9 months): Buy a small, ticketed long call spread on CC (shorter‑dated) to buy optional upside into next 2–3 quarter prints while funding it by selling weekly or monthly OTM calls. Objective: 4x asymmetric payoff if operational improvements exceed expectations; limit premium to <1% of position NAV.